BLTE
Belite Bio, IncNASDAQHealthcare$169.85+0.78%ClosedMarket Cap: $6.68B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
7.45
P/S
0.00
EV/EBITDA
-75.78
DCF Value
$10.53
FCF Yield
-0.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-23.0%
ROA
-9.9%
ROIC
-10.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-28.1M | $-25.3M | $-0.72 | — |
| FY 2025 | $0.00 | NaN% | $-84.2M | $-77.6M | $-2.31 | — |
| Q3 2025 | $0.00 | NaN% | $-23.0M | $-21.7M | $-0.65 | — |
| Q2 2025 | $0.00 | NaN% | $-17.6M | $-16.3M | $-0.50 | — |
| Q1 2025 | $0.00 | NaN% | $-15.5M | $-14.3M | $-0.44 | — |
| Q4 2024 | $0.00 | NaN% | $-11.5M | $-10.1M | $-0.32 | — |
| FY 2024 | $0.00 | NaN% | $-40.0M | $-36.1M | $-1.18 | — |
| Q3 2024 | $0.00 | NaN% | $-9.7M | $-8.7M | $-0.28 | — |
| Q2 2024 | $0.00 | NaN% | $-10.5M | $-9.5M | $-0.31 | — |
| Q1 2024 | $0.00 | NaN% | $-8.3M | $-7.9M | $-0.27 | — |
| Q4 2023 | $0.00 | NaN% | $-7.0M | $-7.0M | $-0.25 | — |
| FY 2023 | $0.00 | NaN% | $-31.7M | $-31.6M | $-1.19 | — |